On August 20, 2025, Denali Capital Acquisition Corp. entered into a Securities Purchase Agreement to sell 1,250,000 shares to a purchaser for $20 million, at $16.00 per share, related to its merger with Semnur Pharmaceuticals. The closing is contingent on conditions and is expected post-merger completion.